Methods and Uses of Anti-IL-23 Antibodies

Abstract

An anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

1 . A method for diagnosing or treating an IL-23 related condition in a cell, tissue, organ or animal, comprising:
 contacting or administering a composition comprising an effective amount of an antibody binding to human IL-23p19 at one or more regions of human IL-23p19 consisting of the amino acid residues selected from the group consisting of residues 93-102, 93-110, and 127-137 of SEQ ID NO:1, with, or to, said cell, tissue, organ or animal.   
     
     
         2 . The method of  claim 1 , wherein the IL-23 related condition is selected from the group consisting of psoriasis, psoriatic arthritis, Crohn's disease, optic neuritis, and clinically isolated syndrome. 
     
     
         3 . The method of  claim 2 , wherein said effective amount is about 0.001-50 mg/kilogram of said cells, tissue, organ or animal. 
     
     
         4 . The method of  claim 2 , wherein said contacting or said administering is by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intraarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal. 
     
     
         5 . The method of  claim 2 , further comprising administering, prior, concurrently or after said contacting or administering, at least one composition comprising an effective amount of at least one compound or polypeptide selected from a detectable label or reporter, an anti-infective drug, a cardiovascular (CV) system drug, a central nervous system (CNS) drug, an autonomic nervous system (ANS) drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid or electrolyte balance, a hematologic drug, an antineoplastic, an immunomodulation drug, an ophthalmic, otic or nasal drug, a topical drug, a nutritional drug, a cytokine, and a cytokine antagonist. 
     
     
         6 . A method for diagnosing or treating an IL-23 related condition in a cell, tissue, organ or animal, comprising:
 contacting or administering a composition comprising an effective amount of an antibody that competitively binds to IL-23p19 with an antibody binding to human IL-23p19 at one or more regions of human IL-23p19 consisting of the amino acid residues selected from the group consisting of residues 93-102, 93-110, and 127-137 of SEQ ID NO:1, with, or to, said cell, tissue, organ or animal.   
     
     
         7 . The method of  claim 6 , wherein the IL-23 related condition is selected from the group consisting of psoriasis, psoriatic arthritis, Crohn's disease, optic neuritis, and clinically isolated syndrome. 
     
     
         8 . The method of  claim 7 , wherein said effective amount is about 0.001-50 mg/kilogram of said cells, tissue, organ or animal. 
     
     
         9 . The method of  claim 7 , wherein said contacting or said administering is by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intraarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal. 
     
     
         10 . The method of  claim 7 , further comprising administering, prior, concurrently or after said contacting or administering, at least one composition comprising an effective amount of at least one compound or polypeptide selected from a detectable label or reporter, an anti-infective drug, a cardiovascular (CV) system drug, a central nervous system (CNS) drug, an autonomic nervous system (ANS) drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid or electrolyte balance, a hematologic drug, an antineoplastic, an immunomodulation drug, an ophthalmic, otic or nasal drug, a topical drug, a nutritional drug, a cytokine, and a cytokine antagonist. 
     
     
         11 . A method for diagnosing or treating an IL-23 related condition in a cell, tissue, organ or animal, comprising:
 contacting or administering a composition comprising an effective amount of an antibody that competitively binds to IL-23p19 with an isolated IL-23p19 antibody, comprising a light chain variable region and a heavy chain variable region, said light chain variable region comprising:
 a complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO:9; 
 a CDRL2 amino acid sequence of SEQ ID NO:10; and 
 a CDRL3 amino acid sequence of SEQ ID NO:11, and said heavy chain variable region comprising: 
 a complementarity determining region heavy chain 1 (CDRH1) amino acid sequence of SEQ ID NO:4; 
 a CDRH2 amino acid sequence of SEQ ID NO:5; and 
 a CDRH3 amino acid sequence of SEQ ID NO:6, with, or to, said cell, tissue, organ or animal. 
   
     
     
         12 . The method of  claim 11 , wherein the IL-23 related condition is selected from the group consisting of psoriasis, psoriatic arthritis, Crohn's disease, optic neuritis, and clinically isolated syndrome. 
     
     
         13 . The method of  claim 12 , wherein said effective amount is about 0.001-50 mg/kilogram of said cells, tissue, organ or animal. 
     
     
         14 . The method of  claim 12 , wherein said contacting or said administering is by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intraarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal. 
     
     
         15 . The method of  claim 12 , further comprising administering, prior, concurrently or after said contacting or administering, at least one composition comprising an effective amount of at least one compound or polypeptide selected from a detectable label or reporter, an anti-infective drug, a cardiovascular (CV) system drug, a central nervous system (CNS) drug, an autonomic nervous system (ANS) drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid or electrolyte balance, a hematologic drug, an antineoplastic, an immunomodulation drug, an ophthalmic, otic or nasal drug, a topical drug, a nutritional drug, a cytokine, and a cytokine antagonist. 
     
     
         16 . Any invention described herein.